Chromoendoscopy Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Absorptive Agents, Contrast Agents, Reactive Agents), By Application (Colorectal, Esophageal, Gastric), By End-Users (Ambulatory Surgery Centers, Diagnostic Centers, Hospitals & Specialty Clinics, Others), By Region, and By Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 0.22 Billion
CAGR (2026-2031)	6.44%
Fastest Growing Segment	Contrast Agents
Largest Market	North America
Market Size (2031)	USD 0.32 Billion

Market Overview

The Global Chromoendoscopy Agents Market will grow from USD 0.22 Billion in 2025 to USD 0.32 Billion by 2031 at a 6.44% CAGR. Chromoendoscopy agents are specialized biochemical stains and dyes applied locally during endoscopic procedures to enhance the visualization of mucosal topography and improve the detection of gastrointestinal lesions. The primary drivers supporting market growth include the increasing global incidence of gastrointestinal malignancies and the rising demand for early diagnostic accuracy to improve patient outcomes. Furthermore, the expansion of national cancer screening programs combined with an aging demographic susceptible to digestive disorders fundamentally underpins the expanding consumption of these diagnostic adjuncts.

A significant challenge impeding market expansion is the growing adoption of virtual chromoendoscopy systems that provide digital tissue enhancement without the time consuming application of physical dyes. This operational efficiency of digital alternatives poses a competitive threat to the routine use of traditional chemical agents. Despite this technological hurdle, the fundamental clinical need remains high due to the prevalence of target diseases. According to the American Cancer Society, in 2025, an estimated 154,270 individuals in the United States are projected to be diagnosed with colorectal cancer.

Key Market Drivers

The Rising Global Incidence of Gastrointestinal Disorders stands as a primary catalyst for the Chromoendoscopy Agents Market, driving an urgent clinical requirement for enhanced visualization tools. As the prevalence of gastrointestinal malignancies escalates, endoscopists increasingly rely on specialized dyes to improve the detection of subtle lesions that conventional imaging might overlook. This trend is particularly critical for colorectal cancer, where early identification of dysplasia significantly impacts survival. According to the International Agency for Research on Cancer (IARC), February 2025, in the 'Colorectal Cancer Awareness Month 2025' statement, there are approximately 1.9 million new cases of colorectal cancer diagnosed worldwide each year. This substantial disease burden ensures a consistent and expanding demand for contrast agents essential for high-definition surveillance and targeted biopsies.

Simultaneously, the Rising Awareness of Colorectal Cancer Screening Programs is fueling market growth by substantially increasing the volume of diagnostic procedures performed globally. National initiatives and public health campaigns are successfully encouraging participation in preventative screenings, thereby creating a larger pipeline of patients requiring endoscopic evaluation with chromoendoscopy adjuncts. According to the National Colorectal Cancer Roundtable, August 2025, in the 'Data and Progress' report, the total number of patients screened for colorectal cancer in U.S. health centers reached 3,617,246 in 2024, reflecting a significant year-over-year increase. This surge in procedural volume is mirrored in the financial performance of key industry players; according to Olympus Corporation, May 2025, in the 'Consolidated Financial Results for Fiscal Year 2025' report, revenue for the Endoscopic Solutions segment increased by 8.4% compared to the previous fiscal year, underscoring the robust expansion of the diagnostic endoscopy sector.

Download Free Sample Report

Key Market Challenges

The primary impediment retarding the growth of the Global Chromoendoscopy Agents Market is the rapid assimilation of virtual chromoendoscopy systems into clinical practice. Unlike traditional techniques that necessitate the manual application of biochemical stains to visualize mucosal topography, digital alternatives enable instant tissue enhancement through integrated endoscopic software. This operational efficiency removes the preparation and cleanup time associated with physical dyes, significantly optimizing workflow for medical staff. Consequently, facilities are increasingly reducing their reliance on consumable staining agents in favor of these built-in digital modalities, directly eroding the recurring revenue streams for chemical agent manufacturers.

This market erosion is particularly critical given the high volume of procedures required to address the global burden of digestive diseases. The substantial demand for screening is progressively being met by digital solutions rather than chemical adjuncts. Illustrating the magnitude of this diagnostic sector, according to the Global Cancer Observatory, in 2024, stomach cancer constituted approximately 4.9% of all new cancer cases reported globally. As clinicians pivot toward digital visualization to manage this caseload, the routine consumption of physical chromoendoscopy agents faces a sustained decline.

Key Market Trends

The Emergence of Oral Delivery Systems is significantly advancing the market by offering a standardized, patient-friendly alternative to traditional dye spraying techniques. This trend focuses on the commercialization of delayed-release methylene blue tablets which disintegrate specifically in the colon, thereby eliminating the inconsistent mucosal coating and procedural delays associated with catheter-based application. The market viability of such pharmaceutical innovations is evident in the robust financial performance of key manufacturers optimizing these proprietary formulations; according to Cosmo Pharmaceuticals, July 2025, in the 'Half-Year Results 2025' announcement, the company reported recurring revenues of €41.9 million for the first half of the year, a figure underpinned by the growing adoption of its proprietary gastrointestinal portfolio including these novel delivery mechanisms.

Simultaneously, the Integration with AI-Assisted Diagnostic Platforms is establishing a new standard of care where chromoendoscopy agents serve as critical contrast enhancers for Computer-Aided Detection (CADe) systems. This synergistic trend capitalizes on the ability of biochemical dyes to highlight subtle mucosal irregularities, which are then analyzed by deep learning algorithms to improve lesion recognition rates and reduce operator dependency. This technological convergence is driving substantial growth within the broader diagnostic sector; according to Fujifilm Holdings Corporation, May 2025, in the 'Financial Results (Consolidated) for the Fiscal Year Ended March 31, 2025', revenue for the Healthcare segment increased to ¥1,022.6 billion, reflecting the surging demand for advanced imaging ecosystems that support these hybrid diagnostic protocols.

Segmental Insights

In the Global Chromoendoscopy Agents Market, the Contrast Agents segment is recognized as the fastest-growing category, driven by the critical need for enhanced visualization during gastrointestinal surveillance. These agents, primarily non-absorbable stains like indigo carmine, function by pooling in mucosal crevices to accentuate surface topography, allowing clinicians to clearly differentiate between neoplastic and benign tissue. This capability is essential for identifying flat or subtle lesions often missed by standard white-light endoscopy. Furthermore, their non-systemic nature offers a favorable safety profile, encouraging widespread adoption among healthcare providers adhering to rigorous colorectal cancer screening guidelines.

Regional Insights

North America maintains a dominant position in the Global Chromoendoscopy Agents Market, driven primarily by the high prevalence of gastrointestinal disorders such as colorectal cancer and inflammatory bowel disease. This regional leadership is supported by a robust healthcare infrastructure that prioritizes early detection and adherence to recommended screening guidelines. Furthermore, the U.S. Food and Drug Administration (FDA) plays a critical role by enforcing rigorous safety standards and approving effective diagnostic solutions, which fosters clinical confidence. The consolidated presence of major pharmaceutical manufacturers in the United States also ensures the consistent availability and adoption of these agents for enhanced endoscopic visualization.

Recent Developments

• In December 2025, Sagent Pharmaceuticals announced a strategic partnership with Provepharm to commercially launch Bludigo (indigotindisulfonate sodium injection) in the United States. This collaboration facilitated the introduction of the first and only FDA-approved indigo carmine diagnostic dye into the U.S. market, addressing a critical need for visualization aids in cystoscopic assessments and other endoscopic procedures. The partnership also outlined plans for the future commercialization of additional diagnostic dyes from Provepharm's pipeline, aiming to expand the availability of high-quality visualization agents for healthcare professionals.
• In December 2024, China Medical System Holdings Limited (CMS) announced the issuance of the first prescription for Lumeblue in China, marking the official commercial launch of the product in the country. Following the regulatory approval obtained earlier in the year, this development signified the transition of the oral methylene blue formulation into clinical application for improving the detection of non-polypoid adenomas and other lesions. The launch leveraged the company’s extensive gastroenterology network to make the diagnostic agent available to patients undergoing colonoscopy screenings across the region.
• In June 2024, Cosmo Pharmaceuticals reported that its partner, China Medical System Holdings Limited (CMS), received approval from the National Medical Products Administration (NMPA) of China for Lumeblue (Methylene Blue MMX). This approval authorized the use of the oral diagnostic drug to enhance the visualization of colorectal lesions during screening and surveillance colonoscopies in adult patients. The product, which utilizes proprietary Multi-Matrix (MMX) technology to deliver the dye directly to the colon, was previously approved in Europe, and this regulatory milestone marked a significant entry into the expanding Chinese market for gastrointestinal diagnostics.
• In April 2024, Laboratoire Aguettant opened a new storage facility at its Saint-Fons site in France as part of a significant €40 million investment strategy to expand its industrial capacity. This expansion included the installation of a new production line for pre-filled syringes at its Champagne site and a new ampoule line at Lyon Gerland, aiming to double the company's production capabilities for essential injectable medicines. The enhanced infrastructure supports the company’s portfolio of pharmaceutical products, which includes dye-based agents used in endoscopic procedures, ensuring a more robust supply chain for hospitals and healthcare providers.

Key Market Players

• Merck & Co., Inc.
• Enzo Life Sciences Inc
• Thermo Fisher Scientific Inc
• Cosmo Pharmaceuticals SA
• Loba Chemie Pvt Ltd
• Provepharm SAS
• Sisco Research Laboratories Pvt Ltd
• Medtronic PLC
• Boston Scientific Corp

By Product	By Application	By End-Users	By Region
Absorptive Agents Contrast Agents Reactive Agents	Colorectal Esophageal Gastric	Ambulatory Surgery Centers Diagnostic Centers Hospitals & Specialty Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chromoendoscopy Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chromoendoscopy Agents Market, By Product:

• Absorptive Agents
• Contrast Agents
• Reactive Agents

• Chromoendoscopy Agents Market, By Application:

• Colorectal
• Esophageal
• Gastric

• Chromoendoscopy Agents Market, By End-Users:

• Ambulatory Surgery Centers
• Diagnostic Centers
• Hospitals & Specialty Clinics
• Others

• Chromoendoscopy Agents Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE